Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities researchers at Jefferies Group lifted their Q1 2019 EPS estimates for Myriad Genetics in a research report issued on Wednesday. Jefferies Group analyst B. Couillard now expects that the company will post earnings of $0.32 per share for the quarter, up from their prior forecast of $0.27. Jefferies Group also issued estimates for Myriad Genetics’ Q2 2019 earnings at $0.34 EPS, Q3 2019 earnings at $0.34 EPS, Q4 2019 earnings at $0.35 EPS and FY2019 earnings at $1.35 EPS.
Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, February 6th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.07. Myriad Genetics had a return on equity of 9.94% and a net margin of 16.67%. The company had revenue of $194.00 million for the quarter, compared to analyst estimates of $188.72 million. During the same period in the prior year, the company posted $0.26 EPS. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year.
Shares of Myriad Genetics (NASDAQ:MYGN) traded down $0.67 during trading hours on Thursday, reaching $33.16. The company had a trading volume of 654,070 shares, compared to its average volume of 773,841. Myriad Genetics has a 12 month low of $15.71 and a 12 month high of $41.57. The firm has a market cap of $2,479.51, a price-to-earnings ratio of 18.30, a P/E/G ratio of 2.26 and a beta of 0.32. The company has a quick ratio of 2.06, a current ratio of 2.34 and a debt-to-equity ratio of 0.09.
In other news, insider Alexander Ford sold 3,031 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Richard M. Marsh sold 37,654 shares of the company’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $40.25, for a total value of $1,515,573.50. Following the completion of the sale, the vice president now owns 157,648 shares in the company, valued at approximately $6,345,332. The disclosure for this sale can be found here. Insiders sold 71,064 shares of company stock worth $2,679,097 in the last 90 days. Company insiders own 6.70% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Myriad Genetics by 0.9% in the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock worth $162,992,000 after buying an additional 56,708 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Myriad Genetics by 4.4% in the third quarter. Dimensional Fund Advisors LP now owns 3,580,081 shares of the company’s stock worth $129,527,000 after buying an additional 149,865 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Myriad Genetics by 18.4% in the fourth quarter. Acadian Asset Management LLC now owns 2,205,297 shares of the company’s stock worth $75,743,000 after buying an additional 343,196 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Myriad Genetics by 31.1% in the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock worth $33,400,000 after buying an additional 306,276 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Myriad Genetics by 7.3% in the third quarter. Russell Investments Group Ltd. now owns 1,151,915 shares of the company’s stock worth $41,676,000 after buying an additional 78,798 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “Myriad Genetics, Inc. (MYGN) Forecasted to Post Q1 2019 Earnings of $0.32 Per Share” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2018/02/08/myriad-genetics-inc-mygn-forecasted-to-post-q1-2019-earnings-of-0-32-per-share.html.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.